A convenient plasmid system for construction of helper-dependent adnoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter

Journal of Gene Medicine

Volumn 8, Issue 4, 2006, Pages 442-451

  Shi, Chang Xin ^a   Graham, Flank L ^a   Hitt, Mary M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adenovirus; Breast cancer; Gene therapy; Mammaglobin promoter; Tissue specificity

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; LUCIFERASE; MAMMAGLOBIN; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENHANCER REGION; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; GENE LOCATION; GENETIC TRANSCRIPTION; HELPER VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SECTION; TISSUE SPECIFICITY; VALIDATION STUDY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; GENE DUPLICATION; GENETIC VECTORS; HELPER VIRUSES; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PLASMIDS; PROMOTER REGIONS (GENETICS); SENSITIVITY AND SPECIFICITY; TRANSDUCTION, GENETIC; UTEROGLOBIN;

ADENOVIRIDAE; ANIMALIA;

EID: 33646242757     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.867     Document Type: Article

References (33)

1. Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999; 10: 2451-2459.
2. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
3. Schiedner GMN, Parks RJ, Wu Y, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18:180-183.
4. Balagué C Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95:820-828.
5. Maione D, Della Rocca C, Giannetti P, et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986-5991.
6. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99: 3923-3930.
7. Belalcazar LM, Merched A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-2732.
8. Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, Karpati G. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 2003; 12: 1287-1299.
9. Shi CX, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 2002; 13: 211-224.
10. Morral N Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1 -antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9:2709-2716.
11. O'Neal WK, Zhou H, Morral N, et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000; 6: 179-195.
12. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
13. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
14. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71: 3293-3298.
15. Shi C-X, Long MA, Liu L, Graham FL, Gauldie J, Hitt M. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not normal non-mammary cells. Mol Ther 2004; 10: 758-767.
16. Hillgenberg M, Schnieders F, Loser P, Strauss M. System for efficient helper-dependent minimal adenovirus construction and rescue. Hum Gene Ther 2001; 12: 643-657.
17. Toietta G, Pastore L, Cerullo V, Finegold M, Beaudet AL, Lee B. Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 2002; 5: 204-210.
18. Sambrook J, Russell WC. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001.
19. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000; 97: 1002-1007.
20. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
21. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 1996; 22: 477-488.
22. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995; 92: 8522-8526.
23. Ng P, Parks RJ, Graham FL. Preparation of helper-dependent adenoviral vectors. Methods Mol Med 2002; 69: 371-388.
24. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
25. Parks R, Evelegh C, Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999; 6: 1565-1573.
26. Ng P, Evelegh C, Cummings D, Graham FL. Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol 2002; 76: 4181-4189.
27. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
28. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
29. Park BJ, Brown CK, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther 1999; 10: 889-898.
30. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res 1996; 56: 5638-5646.
31. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56: 860-865.
32. Wivel NA, Gao G-P, Wilson JM. Adenovirus vectors. In The Development of Human Gene Therapy, Friedmann T (ed). Cold Spring Harbor Laboratory Press: San Diego, CA, 1999; 87-110.
33. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997; 94: 1645-1650.